What is Kaleido?
Founded in 2013, Kaleido (ViCentra) operates at the intersection of precision engineering and patient-centric healthcare. The company specializes in the design and production of advanced insulin pumps, aiming to improve the quality of life for individuals managing diabetes through discreet, user-friendly, and highly reliable hardware. Headquartered in the Netherlands, Kaleido has established itself as a significant entity in the European med-tech ecosystem, leveraging its technical expertise to challenge traditional delivery methods in insulin therapy. Its market position is defined by a focus on innovation, regulatory compliance, and the integration of sophisticated hardware solutions that meet the rigorous demands of modern clinical environments.
How much funding has Kaleido raised?
Kaleido has raised a total of $85.3M across 2 funding rounds:
Series B
$11.3M
Series C
$74M
Series B (1970): $11.3M, investors not publicly disclosed
Series C (2021): $74M led by Health Innovations, INKEF Capital, Partners in Equity, and Life Sciences Partners
Key Investors in Kaleido
INKEF Capital
INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology companies, with a specific emphasis on healthcare and life sciences.
Partners in Equity
Partners in Equity is a private investment firm that supports later-stage growth companies, focusing on sustainable development and long-term value creation across various sectors.
Life Sciences Partners
Life Sciences Partners is a prominent European venture capital firm specializing in the biotech and healthcare sectors, providing strategic guidance and capital to high-growth medical enterprises.
What's next for Kaleido?
With the successful closure of this major strategic investment, Kaleido is poised to enter a new phase of commercial expansion. The company is expected to utilize these resources to scale its manufacturing capabilities, enhance its research and development pipeline, and potentially broaden its market reach beyond its current strongholds. As the demand for integrated diabetes management solutions continues to rise, Kaleido's focus will likely shift toward optimizing its supply chain and deepening its penetration in key international markets. This capital provides the necessary runway to navigate the complexities of the medical device industry while maintaining a competitive edge in product efficacy and patient outcomes.
See full Kaleido company page
